{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:43:47Z","timestamp":1761129827011,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Serum hepatitis B core-related antigen (HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB). We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).<\/jats:p>\n <\/jats:sec>\n Method<\/jats:title>\n Serum HBcrAg was measured in 120 treatment-na\u00efve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF\u2009=\u200960: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). Serum HBcrAg levels were measured at week 0, week 48 and week 96 of NA therapy.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n Among the 120 patients, 67 (55.8%) were hepatitis B e antigen (HBeAg) positive. Both tenofovir and ETV led to significantly lower serum HBcrAg at week 48 and week 96 compared to week 0. There were no significant differences for the magnitude of median HBcrAg decline at week 96 between tenofovir and ETV in HBeAg-positive (2.28 vs. 1.65\u00a0log\u00a0U\/mL, p<\/jats:italic>\u2009>\u20090.05) and HBeAg-negative (0.83 vs. 0.54\u00a0log\u00a0U\/mL, p<\/jats:italic>\u2009>\u20090.05) patients. TDF and TAF produced no significant differences in the magnitude of median HBcrAg decline at week 96 (HBeAg-positive: 2.63 vs. 1.83, respectively; HBeAg-negative: 1.04 vs. 0.40, respectively; both p<\/jats:italic>\u2009>\u20090.05).<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n Magnitude of reduction of HBcrAg levels after 2-year first-line treatment did not differ statistically among the current first-line NAs, although HBcrAg reduction was numerically greater in tenofovir-treated group. More long-term studies are essential to determine whether tenofovir exerts a more pronounced effect on HBcrAg.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12876-021-01711-x","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T10:02:54Z","timestamp":1615975374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Lung-Yi","family":"Mak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka-Shing","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"1711_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"OC Polaris","year":"2018","unstructured":"Polaris OC. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383\u2013403.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"1711_CR2","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","volume":"39","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39(Suppl 1):S50\u20138.","journal-title":"J Hepatol"},{"key":"1711_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886\u201393.","journal-title":"Hepatology"},{"key":"1711_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468\u201375.","journal-title":"Lancet"},{"key":"1711_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/infdis\/jiy391","volume":"219","author":"MH Nguyen","year":"2019","unstructured":"Nguyen MH, Yang HI, Le A, et al. Reduced Incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-a propensity score-matched study. J Infect Dis. 2019;219:10\u20138.","journal-title":"J Infect Dis"},{"key":"1711_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.23952","volume":"53","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62\u201372.","journal-title":"Hepatology"},{"key":"1711_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.24109","volume":"53","author":"H Garg","year":"2011","unstructured":"Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774\u201380.","journal-title":"Hepatology"},{"issue":"67","key":"1711_CR8","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol"},{"key":"1711_CR9","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"1711_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1711_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u201381.","journal-title":"J Hepatol"},{"key":"1711_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5:30\u20136.","journal-title":"JAMA Oncol"},{"key":"1711_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","volume":"19","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhou Y, Yang J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19:511.","journal-title":"BMC Cancer"},{"key":"1711_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/jvh.12688","volume":"24","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, Seto WK, Wong DK, et al. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017;24:654\u201361.","journal-title":"J Viral Hepat"},{"key":"1711_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","volume":"47","author":"LY Mak","year":"2018","unstructured":"Mak LY, Wong DK, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1711_CR16","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1128\/JCM.00366-07","volume":"45","author":"DK Wong","year":"2007","unstructured":"Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942\u20137.","journal-title":"J Clin Microbiol"},{"key":"1711_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","volume":"40","author":"T Kimura","year":"2002","unstructured":"Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439\u201345.","journal-title":"J Clin Microbiol"},{"key":"1711_CR18","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/ctg.2017.51","volume":"8","author":"YF Lam","year":"2017","unstructured":"Lam YF, Seto WK, Wong D, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;8:e125.","journal-title":"Clin Transl Gastroenterol"},{"key":"1711_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","volume":"7","author":"EQ Chen","year":"2017","unstructured":"Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173.","journal-title":"Sci Rep"},{"key":"1711_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/jvh.12971","volume":"25","author":"BG Kim","year":"2018","unstructured":"Kim BG, Park NH, Lee SB, et al. Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat. 2018;25:1565\u201375.","journal-title":"J Viral Hepat"},{"key":"1711_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","volume":"37","author":"DK Wong","year":"2017","unstructured":"Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37:995\u20131001.","journal-title":"Liver Int"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-021-01711-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T10:07:25Z","timestamp":1615975645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01711-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01711-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster, Hong Kong. All subjects provided written<\/i> informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LYM is an advisory board member for Gilead Sciences. WKS received speaker fees, is an advisory board member and received research funding from Gilead Sciences. MFY served as advisor\/ consultant for and received grant\/ research supports from Gilead Sciences. DKW and JF have no potential conflict of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}